IL315174A - Abiraterone decanoate drug metrics and treatment use - Google Patents
Abiraterone decanoate drug metrics and treatment useInfo
- Publication number
- IL315174A IL315174A IL315174A IL31517424A IL315174A IL 315174 A IL315174 A IL 315174A IL 315174 A IL315174 A IL 315174A IL 31517424 A IL31517424 A IL 31517424A IL 315174 A IL315174 A IL 315174A
- Authority
- IL
- Israel
- Prior art keywords
- abiraterone
- decanoate
- prodrugs
- therapy
- decanoate prodrugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263315240P | 2022-03-01 | 2022-03-01 | |
| US202263425839P | 2022-11-16 | 2022-11-16 | |
| PCT/US2023/013116 WO2023167783A1 (en) | 2022-03-01 | 2023-02-15 | Abiraterone decanoate prodrugs and use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315174A true IL315174A (en) | 2024-10-01 |
Family
ID=85724851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315174A IL315174A (en) | 2022-03-01 | 2023-02-15 | Abiraterone decanoate drug metrics and treatment use |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250186463A1 (https=) |
| EP (1) | EP4486353A1 (https=) |
| JP (1) | JP2025508944A (https=) |
| KR (1) | KR20240167653A (https=) |
| CN (1) | CN119136813A (https=) |
| AU (1) | AU2023229152A1 (https=) |
| CA (1) | CA3243913A1 (https=) |
| CL (1) | CL2024002613A1 (https=) |
| CO (1) | CO2024013267A2 (https=) |
| IL (1) | IL315174A (https=) |
| MX (1) | MX2024010741A (https=) |
| WO (1) | WO2023167783A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116490165A (zh) * | 2020-09-02 | 2023-07-25 | 普洛佩拉治疗公司 | 阿比特龙前药 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020081999A1 (en) | 2018-10-18 | 2020-04-23 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| US10792292B2 (en) * | 2019-03-06 | 2020-10-06 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| US11957696B2 (en) | 2021-02-15 | 2024-04-16 | Propella Therapeutics, Inc. | Abiraterone prodrugs |
| JP2024533332A (ja) * | 2021-09-08 | 2024-09-12 | プロペラ セラピューティクス インコーポレイテッド | 経口アビラテロン製剤 |
-
2023
- 2023-02-15 CA CA3243913A patent/CA3243913A1/en active Pending
- 2023-02-15 WO PCT/US2023/013116 patent/WO2023167783A1/en not_active Ceased
- 2023-02-15 EP EP23712635.4A patent/EP4486353A1/en active Pending
- 2023-02-15 US US18/842,725 patent/US20250186463A1/en active Pending
- 2023-02-15 CN CN202380034399.2A patent/CN119136813A/zh active Pending
- 2023-02-15 IL IL315174A patent/IL315174A/en unknown
- 2023-02-15 JP JP2024551978A patent/JP2025508944A/ja active Pending
- 2023-02-15 KR KR1020247032828A patent/KR20240167653A/ko active Pending
- 2023-02-15 AU AU2023229152A patent/AU2023229152A1/en active Pending
- 2023-02-15 MX MX2024010741A patent/MX2024010741A/es unknown
-
2024
- 2024-08-30 CL CL2024002613A patent/CL2024002613A1/es unknown
- 2024-09-30 CO CONC2024/0013267A patent/CO2024013267A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023167783A1 (en) | 2023-09-07 |
| CL2024002613A1 (es) | 2025-02-07 |
| EP4486353A1 (en) | 2025-01-08 |
| MX2024010741A (es) | 2024-09-10 |
| AU2023229152A1 (en) | 2024-09-05 |
| JP2025508944A (ja) | 2025-04-10 |
| CN119136813A (zh) | 2024-12-13 |
| KR20240167653A (ko) | 2024-11-27 |
| CO2024013267A2 (es) | 2024-10-10 |
| US20250186463A1 (en) | 2025-06-12 |
| CA3243913A1 (en) | 2023-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202108331XA (en) | Adjustable expiratory relief in respiratory therapy | |
| IL315174A (en) | Abiraterone decanoate drug metrics and treatment use | |
| IL312286A (en) | Topical compounds and methods for photodynamic therapy | |
| GB202014736D0 (en) | Novel compounds and their use in therapy | |
| GB201820659D0 (en) | Novel compostions and their use in therapy | |
| GB202019475D0 (en) | Therapeutic compounds and their use | |
| GB202108572D0 (en) | Therapeutic compounds and their use | |
| EP4238600A4 (en) | VENTILATION SOUND REDUCTION APPARATUS AND VENTILATION THERAPY DEVICE | |
| IL309249A (en) | Conjugates including phosphoantigens and their use in therapy | |
| IL319234A (en) | Pyrazolylsulfonamide compounds and their use in therapy | |
| IL321265A (en) | Cancer treatment with captopril and fulvestrant | |
| EP4228710A4 (en) | Radiolabeled therapeutic conjugates and their use in therapy | |
| EP4645663A4 (en) | PARALLEL POWER SUPPLY DEVICE AND PROGRAM | |
| IL277905A (en) | The history of hexadecahydro-1H-cyclopenta[A]phenanthrene for the treatment of pain and inflammation | |
| GB202104431D0 (en) | A mycobacterium for use in cancer therapy | |
| EP4401750C0 (en) | COMPOSITION CONTAINS IL-36 AND OPTIONALLY IL-18 FOR USE IN THE TREATMENT OF EYE DISEASES | |
| GB202305546D0 (en) | Novel compounds and their use in therapy | |
| GB202305541D0 (en) | Novel compounds and their use in therapy | |
| GB202102987D0 (en) | Dosimeter apparatus and methods | |
| GB202403391D0 (en) | Novel compounds and their use in therapy | |
| GB202011808D0 (en) | Novel compounds and their use in therapy | |
| PT4284843T (pt) | Sialósidos inovadores e sua utilização em terapia | |
| GB202001209D0 (en) | Novel compounds and their use in therapy | |
| GB202300912D0 (en) | Therapeutic compostions and methods | |
| GB202215141D0 (en) | Novel cell line and its use in therapy |